Who is eligible for clinical trial NCT07792252?

Participants must meet protocol criteria for Major Depressive Disorder (MDD). Confirm exact inclusion and exclusion requirements with the study coordinator.

Does clinical trial NCT07792252 provide travel or cost reimbursement?

Check with the site coordinator at the participating facility for travel and lodging stipend availability, and for which routine-care costs are covered.

🏛️ Verified NIH Record • Updated 2026-08-24

REWIRE: Real-world Engagement With Interventional and Rejoyn Effectiveness (NCT07792252)

🟡 Not Yet Recruiting Interventional Protocol 📊 Observational Clinical Research Sponsor: Yale University

🩺 Plain-English Summary (8th-Grade Level)

Rejoyn is a Prescription Digital Therapeutic (PDT) for adults with Major Depressive Disorder (MDD). This study aims to evaluate the feasibility, engagement, and clinical context of integrating Rejoyn into standard interventional workflows at the Yale New Haven Hospital Interventional Psychiatry Service (IPS). This is a non-significant risk, observational real-world evidence (RWE) study.

Who can join: To join this study, participants generally need to meet the listed inclusion criteria (8 items) and avoid the listed exclusions (5 items).

Location: Yale Greenwich Hospital Interventional Psychiatry Services — Greenwich, Connecticut

📋 "Do I Qualify?" — 1-Minute Self Screener

Instant Checklist

Check every box below. If you can check all of them, you may meet the study's basic screening requirements (final eligibility is confirmed by the site team).

Clinician-confirmed diagnosis of Major Depressive Disorder
Currently being treated with an antidepressant medication
Currently receiving or initiating TMS or esketamine at YNHH IPS
For those receiving TMS, they must be able to initiate Rejoyn within the first two weeks of beginning TMS
Experiencing at least mild depressive symptoms as defined by QIDS of ≥6
Clinician determines patient is appropriate for Rejoyn and prescribes it as part of standard care
Able to access and use a compatible smartphone
Able to provide informed consent for use of clinical data in research

Usually NOT eligible if any of the following apply:

Exclusion Criteria:
Clinician determines Rejoyn is not suitable or safe for the patient
Significant cognitive impairment that prevents app use
Insufficient English proficiency to use Rejoyn
Concurrent participation in another interventional study that would interfere with naturalistic data

🔍 Extracted verbatim from the official NIH eligibility criteria. Always confirm with the study coordinator.

📍 All Participating Trial Locations (2 Sites)

Yale Greenwich Hospital Interventional Psychiatry Services — Greenwich, Connecticut
Yale New Haven Hospital Interventional Psychiatry Services — New Haven, Connecticut

💰 Cost, Insurance & Patient Rights

100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
Voluntary Participation: You may withdraw at any time without affecting your standard medical care.

🏛️ View Official NIH Record ↗